IGC Pharma (NYSE American: IGC) has announced that its management team will participate in Biotech Showcase and BIO Partnering @ JPM, held in-person and scheduled alongside the J.P. Morgan 41st Annual Healthcare Conference 2024. The presentation at Biotech Showcase is slated to begin at 2 p.m. PT on Jan. 8, 2024, while the BIO Partnering event is scheduled for Jan. 9-12, 2024. During the conferences, members of the IGC management team will conduct one-on-one meetings with registered investors and pharmaceutical companies, showcasing the company’s business strategy, recent partnerships and achievements, as well as anticipated milestones. IGC Pharma will additionally host one-on-one meetings in San Francisco during JPM Week.
To view the full press release, visit https://ibn.fm/mHxAF
About IGC Pharma Inc.
IGC Pharma is pioneering innovative solutions to combat Alzheimer’s disease and related challenges. The IGC Pharma portfolio comprises five assets all with a singular mission – to transform the landscape of Alzheimer’s treatment. IGC-AD1 and LMP target neuroinflammation, Aβ plaques and neurofibrillary tangles. IGC-AD1 is currently in a phase 2b clinical trial for agitation in dementia due to Alzheimer’s (clinicaltrials.gov, NCT05543681). TGR-63 targets Aβ plaque to disrupt the progression of Alzheimer’s. IGC-M3 targets the inhibition of Aβ plaque aggregation with the potential to create a profound impact on early-stage Alzheimer’s. IGC-1C targets tau and neurofibrillary tangles in a forward-thinking approach to Alzheimer’s therapy. In parallel, IGC Pharma is at the forefront of generative AI development, with projects including clinical trials, early detection of Alzheimer’s and drug interactions with cannabinoids.
NOTE TO INVESTORS: The latest news and updates relating to IGC are available in the company’s newsroom at https://ibn.fm/IGC
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com
InvestorWire is powered by IBN
